Sandoz CEO Says Biosimilars Are Solution To Access ‘Paradox’
Richard Saynor Also Talks About Lack Of Understanding Of Science Around Biosimilars
Sandoz CEO Richard Saynor says that advances around biosimilars mean that they can offer a simple and meaningful way to help solve the “paradox” of modern healthcare in providing broader access to the latest and best treatments.
You may also be interested in...
The UK’s MHRA has laid out its plans for a biosimilar licensing pathway that will typically not require comparative efficacy data and will consider approved biosimilars interchangeable with their reference products for all indications. Local industry believes the guideline creates an opportunity for the UK to be the first launch market for biosimilars.
Laurus Labs has reported a 70% jump in annual revenues after what the company described as an “extraordinary year.” The firm has decided to expand its current capacities to meet the increased demand for third-party API sales and is looking to file eight to ten ANDAs next year as it sees “many long-term opportunities in the US generics space.”
Bangladesh’s Beximco has reported growth in export sales on the back of the company’s expansion into new international markets. The company delivered strong financial results overall for the third quarter of fiscal 2021, including double-digit growth on the domestic front.